ArticleCardiovascular diabetology2018
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Hunting for a coronary artery disease diagnosis in asymptomatic patients with diabetes mellitus: if, how and when.Cardiovascular diabetology · 2025Review
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Relationship between serum uric acid and ventricular diastolic dysfunction in type 2 diabetes mellitus patients.American journal of translational research · 2025Article
- Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.Cardiovascular diabetology · 2022Review
- Ameliorative effects of Carica papaya extracts against type II diabetes-induced myocardial pathology and dysfunction in albino rats.Environmental science and pollution research international · 2021Article
- High prevalence of prolonged QTc interval among individuals in ambulatory diabetic care in southwestern Uganda.International journal of diabetes in developing countries · 2021Article
- Assessment of electrocardiogram abnormality and associated factors among apparently healthy adult type 2 diabetic patients on follow-up at Jimma Medical Center, Southwest Ethiopia: Cross-sectional study.BMC cardiovascular disorders · 2021Article
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.Cardiovascular diabetology · 2020Article
- Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project.Cardiovascular diabetology · 2019Article
- Left Ventricular Diastolic Dysfunction in Type 2 Diabetes-Progress and Perspectives.Diagnostics (Basel, Switzerland) · 2019Review
- SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.BMC endocrine disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.